LU88778I2 - Anastrozole optionellement sous forme d'un sel d'addition d'acide pharmaceutiquement acceptable (Arimidex (R)) - Google Patents

Anastrozole optionellement sous forme d'un sel d'addition d'acide pharmaceutiquement acceptable (Arimidex (R))

Info

Publication number
LU88778I2
LU88778I2 LU88778C LU88778C LU88778I2 LU 88778 I2 LU88778 I2 LU 88778I2 LU 88778 C LU88778 C LU 88778C LU 88778 C LU88778 C LU 88778C LU 88778 I2 LU88778 I2 LU 88778I2
Authority
LU
Luxembourg
Prior art keywords
radical
cyano
hydroxy
alkyl
alkoxy
Prior art date
Application number
LU88778C
Other languages
English (en)
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10618970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU88778(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of LU88778I2 publication Critical patent/LU88778I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
LU88778C 1987-06-16 1988-06-14 Anastrozole optionellement sous forme d'un sel d'addition d'acide pharmaceutiquement acceptable (Arimidex (R)) LU88778I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878714013A GB8714013D0 (en) 1987-06-16 1987-06-16 (substituted-aralkyl)heterocyclic compounds

Publications (1)

Publication Number Publication Date
LU88778I2 true LU88778I2 (fr) 1996-11-05

Family

ID=10618970

Family Applications (1)

Application Number Title Priority Date Filing Date
LU88778C LU88778I2 (fr) 1987-06-16 1988-06-14 Anastrozole optionellement sous forme d'un sel d'addition d'acide pharmaceutiquement acceptable (Arimidex (R))

Country Status (21)

Country Link
US (2) US4935437A (fr)
EP (1) EP0296749B1 (fr)
JP (1) JP2609290B2 (fr)
AT (1) ATE113277T1 (fr)
AU (1) AU605872B2 (fr)
CA (1) CA1337420C (fr)
DE (1) DE3851914T2 (fr)
DK (1) DK174573B1 (fr)
ES (1) ES2063036T3 (fr)
FI (1) FI97804C (fr)
GB (1) GB8714013D0 (fr)
HU (1) HU211142A9 (fr)
IE (1) IE65570B1 (fr)
IL (1) IL86499A (fr)
LU (1) LU88778I2 (fr)
MX (1) MX9202876A (fr)
NL (1) NL970012I2 (fr)
NO (2) NO170080C (fr)
NZ (1) NZ225037A (fr)
PT (1) PT87720B (fr)
ZA (1) ZA883691B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810067D0 (en) * 1988-04-28 1988-06-02 Ucb Sa Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
NZ236440A (en) * 1989-12-15 1993-07-27 Merck & Co Inc Reversal of sexual phenotype in poultry using an inhibitor of steroid biotransformation and/or aromatase inhibitor, poultry produced by this process
AU7124691A (en) * 1990-02-27 1991-08-29 Ciba-Geigy Ag Benzofurans
EP0457716A1 (fr) * 1990-04-20 1991-11-21 Ciba-Geigy Ag Dérivés de naphtaline
TW224461B (fr) * 1990-09-18 1994-06-01 Ciba Geigy Ag
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
CH683151A5 (de) * 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
KR100219760B1 (ko) * 1996-03-13 1999-09-01 김성환 보온 단열재
GB0012293D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
GB0129457D0 (en) * 2001-12-10 2002-01-30 Astrazeneca Ab Method of treatment
WO2005105762A1 (fr) * 2004-05-05 2005-11-10 Natco Pharma Limited Procede ameliore pour la preparation d'une anastrozole a purete elevee
GB0412492D0 (en) 2004-06-04 2004-07-07 Sterix Ltd Compound
GB0414120D0 (en) * 2004-06-24 2004-07-28 Generics Uk Ltd Novel processes and intermediates
DE102005037484A1 (de) * 2004-08-09 2006-02-23 Chemagis Ltd. Neue Verfahren zur Herstellung von im Wesentlichen reinem Anastrozol
EP1845973B1 (fr) 2005-01-21 2015-08-12 Astex Therapeutics Limited Composes pharmaceutiques
US20060189670A1 (en) * 2005-02-22 2006-08-24 Glenmark Pharmaceuticals Limited Process for the preparation of anastrozole and intermediates thereof
EP1705168A1 (fr) * 2005-03-21 2006-09-27 Helm AG Procédé amelioré de bromuration d'alkylbenzènes dans la chaine laterale
CA2601649A1 (fr) * 2005-04-06 2006-10-12 Sicor Inc. Procede de preparation de medicaments anticancereux
US20070032660A1 (en) * 2005-06-27 2007-02-08 Alessandro Pontiroli Purification process for Anastrozole intermediate
WO2007002722A2 (fr) * 2005-06-27 2007-01-04 Sicor, Inc. Procédé de purification d'un intermédiaire de l'anastrozole
US20090221837A1 (en) * 2005-09-30 2009-09-03 Kirtipalsinh Saijansinh Solanki Process for the Preparation of Pure Anastrozole
WO2007039913A1 (fr) * 2005-10-05 2007-04-12 Usv Limited Procede de preparation de 2,2'-[5-(1,2,4-triazole-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile).
WO2007039919A1 (fr) * 2005-10-06 2007-04-12 Natco Pharma Limited Formes cristallines d'anastrozole
US20070100148A1 (en) * 2005-10-31 2007-05-03 Veerender Murki Process for preparing anastrozole
WO2007105231A1 (fr) * 2006-03-10 2007-09-20 Shilpa Medicare Ltd. Procédé amélioré permettant de préparer un anastrozole a haut degré de pureté
AR061016A1 (es) * 2006-05-19 2008-07-30 Synthon Bv Proceso para la purificacion de anastrozol
US8058302B2 (en) * 2006-06-05 2011-11-15 Cadila Healthcare Limited Process for preparing pure anastrozole
WO2008034644A2 (fr) * 2006-09-22 2008-03-27 Synthon B.V. Procédé de fabrication d'anastrozole
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US7989636B2 (en) * 2006-10-17 2011-08-02 Cipla Limited Process for the preparation of pure anastrozole
US20080177081A1 (en) * 2007-01-19 2008-07-24 Formosa Laboratories, Inc. Process for Preparation of Anastrozole
CN101307027B (zh) * 2007-05-17 2011-09-07 杜焕达 一种阿那曲唑的新的制备方法
WO2009018811A1 (fr) * 2007-08-06 2009-02-12 Schebo Biotech Ag Nouveaux médicaments, procédé pour leur production et leur utilisation thérapeutique médicale
MX2010004195A (es) 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
WO2009128919A1 (fr) * 2008-04-15 2009-10-22 Concert Pharmaceuticals, Inc. Analogues d'anastrozole portant du deutérium en tant qu'inhibiteurs d'aromatase pour le traitement du cancer du sein
US20100111901A1 (en) * 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
DE102010046464A1 (de) 2009-03-19 2011-04-21 Amw Gmbh Transdermales System mit Aromatasehemmer
EP2343278A1 (fr) 2010-01-07 2011-07-13 Hexal AG Procédé de préparation de dérivés de phényle trisubstitué comprenant un groupe (1H-1,2,4-triazol-1-yl)alkyle
DE102010026883A1 (de) 2010-03-11 2011-12-15 Amw Gmbh Transdermales System mit Aromatasehemmer
MX2014009322A (es) 2012-02-29 2014-11-10 Repros Therapeutics Inc Terapia de combinacion para el tratamiento de la deficiencia androgenica.
CN103172580B (zh) * 2013-03-29 2015-04-22 凯莱英医药集团（天津）股份有限公司 一种阿那曲唑的制备方法
ITRM20130285A1 (it) 2013-05-14 2014-11-15 Corden Pharma Latina S P A Con Uni Co Socio Metodo per la preparazione di anastrozolo di grado farmaceutico
CN103342663B (zh) * 2013-07-15 2015-07-29 凯莱英医药集团（天津）股份有限公司 一种阿那曲唑关键中间体的制备方法
CN104387332B (zh) * 2014-11-27 2016-04-13 江苏正大清江制药有限公司 一种合成芳香化酶抑制剂的方法
US11633382B2 (en) 2015-11-10 2023-04-25 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
CN106083748B (zh) * 2016-06-21 2019-08-16 扬子江药业集团江苏海慈生物药业有限公司 一种阿那曲唑的制备方法
CN115611731A (zh) * 2021-04-26 2023-01-17 成都伊诺达博医药科技有限公司 一种依洛昔巴特中间体的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2431407C2 (de) * 1974-06-29 1982-12-02 Bayer Ag, 5090 Leverkusen 1,2,4-Triazol-1-yl-alkanone und -alkanole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Fungizide
JPS55313A (en) * 1978-06-13 1980-01-05 Kissei Pharmaceut Co Ltd Imidazole derivative
CA1134828A (fr) * 1978-12-28 1982-11-02 Tadao Tanouchi Derives de la pyridine
NZ206968A (en) * 1983-02-02 1986-06-11 Lilly Co Eli Pyrimidine derivatives pharmaceutical formulations
US4766140A (en) * 1984-06-18 1988-08-23 Eli Lilly And Company Method of inhibiting aromatase
US4755526A (en) * 1984-06-18 1988-07-05 Eli Lilly And Company Method of inhibiting aromatase
US4801594A (en) * 1984-06-18 1989-01-31 Eli Lilly And Company Aromatase inhibitors
GB2162513B (en) * 1984-06-25 1988-01-20 Toyama Chemical Co Ltd Dihydropyridine derivatives
US4699652A (en) * 1985-07-22 1987-10-13 Hoffmann-La Roche Inc. Fungicidal pyridine derivatives for use in agriculture
EP0228995A1 (fr) * 1985-12-20 1987-07-15 Ciba-Geigy Ag Microbicides
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
ES2016660B3 (es) * 1987-01-21 1990-11-16 Ciba-Geigy Ag Agente microbicida.

Also Published As

Publication number Publication date
JPS6419067A (en) 1989-01-23
ES2063036T3 (es) 1995-01-01
MX9202876A (es) 1992-06-30
NO170080B (no) 1992-06-01
CA1337420C (fr) 1995-10-24
ZA883691B (en) 1989-02-22
NO882628D0 (no) 1988-06-15
AU605872B2 (en) 1991-01-24
HK1000206A1 (en) 1998-02-06
EP0296749A1 (fr) 1988-12-28
FI97804B (fi) 1996-11-15
GB8714013D0 (en) 1987-07-22
US4935437A (en) 1990-06-19
DK330488A (da) 1988-12-17
PT87720A (pt) 1988-07-01
ATE113277T1 (de) 1994-11-15
JP2609290B2 (ja) 1997-05-14
IL86499A (en) 1997-09-30
NO1997006I1 (no) 1997-05-16
NO170080C (no) 1992-09-09
FI882882A7 (fi) 1988-12-17
IE65570B1 (en) 1995-11-01
EP0296749B1 (fr) 1994-10-26
IE881505L (en) 1988-12-16
HU211142A9 (en) 1995-10-30
NO882628L (no) 1988-12-19
FI97804C (fi) 1997-02-25
IL86499A0 (en) 1988-11-15
AU1691188A (en) 1988-12-22
PT87720B (pt) 1992-10-30
DE3851914D1 (de) 1994-12-01
NL970012I2 (nl) 1997-07-01
DK330488D0 (da) 1988-06-16
USRE36617E (en) 2000-03-14
DK174573B1 (da) 2003-06-23
DE3851914T2 (de) 1995-03-23
NL970012I1 (nl) 1997-05-01
FI882882A0 (fi) 1988-06-16
NZ225037A (en) 1991-10-25

Similar Documents

Publication Publication Date Title
NO1997006I1 (no) Anastrozol/<alfa>,<alfa>,<alfa>',<alfa>'-tetrametyl-5(1H-1,2,4-triazol-1-ylmetyl)-m-benzendiatonitril
KR920701167A (ko) 약제학적 활성 화합물
KR900004333A (ko) 맥관 형성 억제제
BG60032B2 (bg) Метод за получаване на триазолни производни
GR3017100T3 (en) Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same.
KR900003157A (ko) 트리아졸 항진균제
KR950005825A (ko) 4-아미노피리미딘 유도체
EP0299683A3 (fr) Composés oléfinique hétérocycliques et leur utilisation comme inhibiteurs d'aromatase
CA2084334A1 (fr) Derives du triazole et leurs sels, procedes pour les preparer et agent antifongique les renfermant
KR920016456A (ko) 5-(치환 아미노) -1,2,4-트리아졸로 [1,5-a]피리미딘 유도체
IE821721L (en) Imidazole derivatives
KR840007226A (ko) 트리아졸 유도체의 제조방법
KR950032178A (ko) 치환된 피라졸린 유도체
IE830773L (en) 1,2,4-triazole derivatives.
CA2542361A1 (fr) Derive d'azole utiles en tant qu'agents antifongiques, ayant une interaction limitee avec les cytochromes metaboliques
DK308787A (da) Triazol- og imidazolforbindelser
KR870004979A (ko) 할로알콕시 치환된 2-(1h-1,2,4-트리아졸릴)-1-페닐에탄-1-온 케탈을 함유하는 살균제
KR840008801A (ko) 아졸 유도체의 제조방법
KR880007474A (ko) 치환된 피라졸린-5-온 유도체계 제초제 및 살진균제
KR890002051A (ko) 복소환식 화합물
KR900000360A (ko) 2,4-디히드로-3h-1,2,4-트리아졸-온 유도체
KR930010033A (ko) 광학적 활성 아졸 화합물, 그의 제조방법 및 용도